10-17-07

OCT 16 2007 W

CASE 4-19919/A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.30

Express Mail Label Number

Date of Deposit

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1203

GOSCHKE ET AL.

Patent No. 5,559,111

Issued September 24, 1996

**APPLICATION NO: 08/416,242** 

FILED: APRIL 4, 1995

FOR: NOVEL DELTA-AMINO-GAMMA-HYDROXY-OMEGA-ARYL-

**ALKANOIC ACID AMIDES** 

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

Certificate

OCT 1 9 2007

of Correction

## **FEE\_LETTER**

Sir:

Enclosed herewith is a Disclaimer inPatent under 37 CFR 1.321 in the above-identified Patent.

The Commissioner is hereby authorized to charge the \$130 fee under 37 CFR §1.20(d) and any additional fees that may be required to Deposit Account No. 19-0134 in the name of Novartis. An additional copy of this paper is here enclosed.

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Building 104

East Hanover, NJ 07936-1080 (862) 778-7831

(002) 110-103

Date: October 15, 2007

Gregory D/Ferraro Attorney for Applicants

Reg. No. 36,134

PTO/SB/43 (10-07)
Approved for use through 10/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE حمدة. der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DISCLAIMER IN PATENT UNDER 37 CFR 1.321(a)	
Name of Patentee Novartis Corporation	Docket Number (Optional) 19919
Patent Number 5,559,111	Date Patent Issued September 24, 1996
Title of Invention	
δ-AMINO-γ-HYDROXY-ω-ARYL-ALKANOIC ACID AMIDES	
I hereby disclaim the following complete claims in the above identified patent:	
The extent of my interest in said patent is (if assignee of record, state liber and page, or reel and frame, where assignment is recorded): Assignee of record: Assignment from inventors to Ciba-Geigy Corp. was recorded on April 29, 1996 at Reel 007916, Frame 0856 and the change of name from Ciba-Geigy Corp. to Novartis Corp. was recorded on The fee for this disclaimer is set forth in 37 CPR 20(3).  Patentee claims small entity status. See 37 CFR 1.27.  Small entity status has already been established in this case, and is still proper.  A check in the amount of the fee is enclosed.  Payment by credit card. Form PTO-2038 is attached.  The Director is hereby authorized to charge any fees which may be required or credit any overpayment to Deposit Account No. 190134 I have enclosed a duplicate copy of this form.  WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
Signed at Florham Park State of New Jersey this 15th day of October 2007	
/ / Signature	Registration Number, if applicable
Gregory Ferraro	862-778-7831
Typed or printed name of patentee/ attorney or agent of r	ecord Telephone Number
One Health Plaza, Bldg. 104, East Hanover, NJ 07936-1080	
Address	
City, State, Zip Code or Foreign Country as applicable	

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.** 

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.